AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults
Plozasiran specifically targets and reduce the production of APOC3, thereby reducing triglyceride levels and lowering the ...
Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk
Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...
Zacks Small Cap Research on MSN6h
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…
ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...
Hosted on MSN7mon
Plozasiran reduces triglyceride levels by 74% at 24 weeks
"Plozasiran produced significant reductions in triglyceride levels below the threshold associated with elevated risk for pancreatitis, with a favorable safety profile," said Daniel Gaudet, MD, Ph ...
Morningstar15d
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead also intends to submit applications for approval of investigational plozasiran for the treatment of patients with FCS to additional regulatory authorities in 2025. “The NDA submission ...
Yahoo Finance15d
AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults
On 16 November, during the American Heart Association (AHA) 2024 Annual Scientific Sessions in Chicago, IL, USA, findings from the Phase III PALISADE (NCT05089084) clinical trial of plozasiran ...
FiercePharma28d
Arrowhead targets rare disease patients, pushing message that hope is on the horizon
The biotech is developing plozasiran, a siRNA candidate designed to silence APOC3, for the treatment of conditions including familial chylomicronemia syndrome (FCS). People with the rare genetic ...
Nasdaq15d
Arrowhead submits plozasiran NDA to FDA
Arrowhead (ARWR) announced that it submitted a new drug application, or NDA, to the FDA for investigational plozasiran for the treatment of familial chylomicronemia syndrome, or FCS, a severe and ...
Nasdaq15d
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
The NDA submission is supported by the SUMMIT program of clinical studies of plozasiran and positive findings in the Phase 3 PALISADE study. PALISADE successfully met its primary endpoint and all ...
Morningstar7d
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which is a component ...
Business Wire15d
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
“In the Phase 3 PALISADE study in patients with and without a genetic confirmation of familial chylomicronemia syndrome (FCS), plozasiran induced deep and sustained reductions in triglycerides ...